A phase 1 clamp trial shows tirzepatide improves beta-cell function and insulin sensitivity more than semaglutide, explaining its glucose-lowering. PICO summary and commentary.
Welcome to Hormone Insight. Our mission is to support clinical decision-making with accessible, evidence-based insights from recent studies and trials.
CATEGORIES
© 2024-2026 Hormone Insight. All rights reserved.